Genoa is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis and other severe respiratory diseases. The Company's lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. Genoa's experienced clinical and inhaled product development team is rapidly advancing Aerodone for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.